A tumour marker is a chemical that is produced by tumour cells and can be measured in the blood or other body fluids. It may be used to detect the presence of a tumour and subsequently to monitor the progress of the disease and response to treatment. An ideal tumour marker (which remains to be discovered) would have a cut-off point where there would be no false positives or negatives (screening tests).
Recent technological advances have allowed the evaluation of a large number of chemicals as potential tumour markers. In gynaecology there are three tumour markers of proven value Ca125, HCG and alpha-fetoprotein. Ca125 is a tumour marker that is associated with ovarian cancer. Some ovarian cancers may not result in an increase in Ca125 levels. There are several reasons that limit the value of currently available tumour markers. Most tumour-associated markers are also produced by healthy tissues so that there is an overlap of levels between those with a tumour and healthy people. Ca125, the ovarian cancer marker, increases in 20% of healthy women during their periods and in 50% of women during pregnancy. It is non-specific and may be increased in some endometrial or bowel cancers. Raised levels may also be found in association with benign conditions of the ovary, pelvic inflammation and endometriosis. The pre-placental tissue of pregnancy (trophoblast) produces human chorionic gonadotrophic hormone (HCG) and its presence is the first evidence of pregnancy. Occasionally (about one pregnancy in a thousand) in the UK, the trophoblast becomes an innocent tumour (hydatidiform mole). Rarely, this may become malignant choriocarcinoma; HCG levels are useful to monitor patients who have had a hydatidiform mole. Disgerminomas, (rare ovarian tumours in young women) may result in high levels of HCG. Alpha-fetoprotein (AFP) is produced by foetal tissues. When there is an open spina bifida the levels of AFP in the amniotic fluid and mother's blood rise. This was the first useful test for detecting spina bifida during pregnancy but has become superseded by ultrasound examination of the fetus. AFP levels may be increased in association with some rare
germ cell tumours of the ovaries.
Related Medical Abstracts - Click on the paper title:-
Please click on the required question.
- 1 What is cancer (malignancy)
- 2 What is meant by cancer staging?
- 3 How prevalent is cancer?
- 4 How prevalent are womens' cancers?
- 5 What causes cancer?
- 6 Is cancer a hereditary condition?
- 7 How can gynaecological cancer present?
- 8 How can we reduce the risks of the womens' cancers?
Reducing the Risks of Womens' Cancers.
- 9 What are screening tests?
- 10 What are the reactions to a diagnosis of cancer?
- 11 Is there a place for counselling when cancer is diagnosed?
- 12 Can personality alter the prognosis?
- 13 Is the incidence of deaths from the female cancers changing?
- 14 Is there a place for a holistic approach to cancer?
Cancer of the Cervix.
- 15 How prevalent is cervical cancer?
- 16 What causes cervical cancer?
- 17 How long an interval should there be between cervical screening (smear) (PAP) tests?
- 18 Is there any evidence that cervical screening can reduce the incidence of cervical cancer?
- 19 Will pre-malignant changes of the cervix invariably lead to cancer?
Endometrial Cancer (Uterus)
- 20 What causes endometrial cancer?
- 21 Are there screening tests for endometrial cancer?
- 22 How does endometrial cancer present?
- 22a How can endometrial cancer be prevented?
- 22b How can endometrial cancer be treated?
Cancer of the Ovary.
- 23 How does ovarian cancer present?
- 24 How prevalent is ovarian cancer?
- 25 What are tumour markers?
- 26 Can we screen for ovarian cancer?
- 27 What is the relationship between infertility and ovarian cancer?
- 28 Can treatment of infertility increase the risk of ovarian cancer?
- 29 What is the relationship between oral contraception and cancer?
- 30 Can ovarian cancer be prevented?
- 31 I use talcum power. Could this increase my risk of developing ovarian cancer?
The Treatment Of Womens' Cancers
- 32 Can we predict the course of a cancer?
- 33 What treatment options are available for gynaecological cancer?
- Q32.33c What treatment options are available for ovarian cancer?
Cancer of the Vulva, Vagina and Fallopian Tube
- 34 How prevalent are malignant conditions of the vulva, vagina and Fallopian tubes?
Breast Cancer
- 35 What is the incidence of breast cancer?
- 35 ?What is the cause of breast cancer?
- 35a What are the advantages of breast cancer screening - mammography - mammograms?
- 14 Is there a place for a holistic approach to cancer?
- 36 How often should breast screening be carried out?
- 37 Are there any problems having a mammogram?
- 38 Should I check myself for breast lumps?
- 39 One of my family developed cancer of the breast. Am I at increased risk?
- 40 We have a family tendency towards developing breast / ovarian cancer. Are there any genetic tests to find out if I am at increased risk?
- 41 What happens if a mammogram shows an abnormality?
- 42 What are the advantages and disadvantages of tamoxifen in the management of breast cancer?
- 42a Breast Cancer Treatment - What is available?
- 43 What is the relationship between breast cancer and the pill?
Web sites and Support Groups
- 44 Are there any support groups?
- 44 Are there any support groups?
- 45 Support Groups.
- 46 Breast Cancer Support Groups
- 47 Ovarian Cancer Support Groups
- 48 Endometrial Cancer Support Groups
- 49 Cervical Cancer Support Groups
Thank you for choosing to visit us.
This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT.
I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.














